FINWIRES · TerminalLIVE
FINWIRES

HKG:2162

7 stories mentioning HKG:2162Updated just now

Every FINWIRES story that references HKG:2162, newest first.

Asia

Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets

Keymed Biosciences (HKG:2162) has signed a licensing agreement with Singapore-based Aeira to market and sell Kangyueda in 18 markets across Central and Southeast Asia, according to a Wednesday bourse filing.Kangyueda is approved to treat moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis, the filing said.Under the deal, Keymed will receive an upfront payment, milestone payments upon hitting certain targets and royalties in the high-double-digit percentage range based on regional sales.Aeira will be responsible for regulatory filings and the commercialization of Kangyueda in markets including Singapore, Malaysia, the Philippines, Thailand, Kazakhstan and Uzbekistan, as well as Hong Kong and Macau.Keymed will oversee the production and timely supply of Kangyueda to Aeira.

HKG:2162
Asia

Keymed Biosciences' Nasal Polyp Drug Trial Meets All Phase 2 Endpoints

Keymed Biosciences (HKG:2162) said its Phase 2 trial of CM512, a TSLP/IL-13 bispecific antibody, in patients with chronic rhinosinusitis with nasal polyps met all study endpoints, according to a Monday filing with the Hong Kong bourse.CM512 rapidly reduced nasal polyp size and nasal congestion, with efficacy from a single dose sustained for six months.The drug also showed favorable safety and tolerability, with no serious adverse events reported in treatment groups.

HKG:2162
Asia

Hong Kong Stocks Edge Higher Ahead of Central Bank Meetings; Keymed Biosciences Falls

Hong Kong stocks closed higher on Tuesday as investors await key central bank meetings and earnings from major U.S. technology companies.The Hang Seng Index gained 103.67 points, or 0.4%, to close at 25,310.85, while the Hang Seng China Enterprises Index rose 70.87 points, or 0.9%, to 8,436.25.Hong Kong technology shares were a little resilient as compared to regional peers even as renewed concerns over artificial intelligence spending triggered another selloff in global chipmakers and weighed on broader Asian markets.Sentiment also drew support from optimism over China's semiconductor industry after CXMT Corp.'s Shanghai debut and reports of China's progress in domestic immersion DUV lithography technology.Among individual stocks, Keymed Biosciences (HKG:2162) fell nearly 6% after reporting that its global phase 3 trial of CMG901, conducted with AstraZeneca, met its primary endpoint in patients with CLDN18.2-positive advanced gastric cancer.

Hang SengHKG:2162
Asia

Keymed Biosciences' Gastric Cancer Drug Meets Phase 3 Goal; Shares Fall 5%

Keymed Biosciences (HKG:2162) and AstraZeneca's global phase 3 trial of CMG901 met its primary endpoint in patients with CLDN18.2-positive advanced gastric cancer, according to a Tuesday filing with the Hong Kong bourse.The trial showed the antibody-drug conjugate significantly improved overall survival compared with investigator's choice of treatment in patients receiving second- or later-line therapy.CMG901 demonstrated a safety profile consistent with previous studies, with no new safety signals identified, the company said.Following the positive Phase 3 results, the company estimates peak annual sales of $3 billion to $5 billion for the drug candidate.Shares of the biopharmaceutical company were down over 5% in recent trade.

HKG:2162
Asia

Keymed Biosciences' CM512 Gets Breakthrough Therapy Designation in China; Shares up 4%

Keymed Biosciences (HKG:2162) said its investigational drug CM512 received breakthrough therapy designation from the Center for Drug Evaluation of China's National Medical Products Administration for the treatment of chronic rhinosinusitis with nasal polyps.The designation comes as the company's randomized, double-blind Phase II clinical trial evaluating the safety and efficacy of the injection remains ongoing, according to a Hong Kong bourse filing on Thursday.Shares of the company rose nearly 4% in recent trade.

HKG:2162
Asia

Keymed Biosciences Expects Return to Profit in H1

Keymed Biosciences (HKG:2162) expects to report a profit of at least 1.2 billion yuan for the first half of 2026, compared with a loss of about 79 million yuan a year earlier, according to a Wednesday filing with the Hong Kong bourse.The company attributed the turnaround to an upfront payment from the sale of its minority stake in Ouro Medicines, milestone payments from AstraZeneca tied to CMG901, strong Kangyueda sales, and tighter cost controls.

HKG:2162
Asia

Keymed Biosciences Receives $257 Million Upfront Payment After Gilead-Ouro Deal Close

Keymed Biosciences (HKG:2162) received an upfront payment of $257 million following the completion of Gilead Sciences' acquisition of Ouro Medicines, according to a Friday Hong Kong bourse filing.Under the transaction, Gilead acquired all equity interests in Ouro Medicines for an upfront payment of $1.68 billion and potential milestone payments of up to $500 million.The company said its existing licensing agreement with Ouro Medicines remains in effect, preserving its eligibility for up to $610 million in development and commercial milestones, as well as tiered royalties on net sales.

HKG:2162

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2162 in your portfolio
WheelAI
WheelAI
Analyze HKG:2162 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2162